Recruiting PHASE2 INTERVENTIONAL 2-arm NCT06241846

A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC

A Multicenter, Open-Label, Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With Metastatic Castration-Resistant Prostate Cancer

Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.

Conditions Metastatic Castration-resistant Prostate Cancer (mCRPC)

Interventions YL201 for Injection

Updated 7 times since 2024 Last updated: Aug 25, 2025 Started: Feb 22, 2024 Primary completion: Feb 28, 2027 Completion: Feb 28, 2029

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Metastatic Castration-resistant Prostate Cancer (mCRPC), this trial is actively recruiting participants. The trial is conducted by MediLink Therapeutics (Suzhou) Co., Ltd. and has accumulated 7 data snapshots since 2024. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Recruiting PHASE2
Nov 2024 — Sep 2025 [monthly]

Recruiting PHASE2
Sep 2024 — Nov 2024 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
May 2024 — Jul 2024 [monthly]

Recruiting PHASE2

▶ Show 2 earlier versions

Apr 2024 — May 2024 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Mar 2024 — Apr 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Feb 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

MediLink Therapeutics (Suzhou) Co., Ltd.

Data source: MediLink Therapeutics (Suzhou) Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Beijing, China , Chengdu, China , Chongqing, China , Guangzhou, China , Hangzhou, China , Harbin, China , Hefei, China , Hunan, China , Jinan, China , Nanjing, China and 8 more locations